Tennessee CBD-Oil Qualifying Conditions

Last verified: May 2026

The Nine Qualifying Conditions (Post-2021 Expansion)

Per T.C.A. § 39-17-402(16)(F) as amended by 2021 Public Chapter 577 (SB 118):

1. Alzheimer’s disease
2. Amyotrophic lateral sclerosis (ALS)
3. Cancer — end-stage or with treatment producing wasting, recalcitrant nausea/vomiting, or pain
4. Inflammatory bowel disease — Crohn’s disease, ulcerative colitis
5. Epilepsy or intractable seizures
6. Multiple sclerosis (MS)
7. Parkinson’s disease
8. HIV / AIDS
9. Sickle cell disease
10. Any other condition added by TMCC rule (none added to date)

What Is Conspicuously Missing

The list excludes the conditions that drive most U.S. medical-cannabis enrollment:

• Chronic pain — the largest category in nearly every operating medical-cannabis program (Florida, Pennsylvania, Maryland, New Mexico, Oklahoma, Arkansas, Mississippi, Louisiana, etc.).
• PTSD — covered in most veteran-friendly programs (Pennsylvania, Mississippi, Louisiana, New Mexico, Arkansas, Maryland) but not in Tennessee.
• Anxiety — not on the Tennessee list; addressed in some programs (West Virginia partial, Pennsylvania post-2024 expansion).
• Depression — not covered.
• Nausea from sources other than cancer treatment — not covered.
• Glaucoma, cachexia, terminal illness, ALS-adjacent neurodegenerative — some captured by the nine, most not.
• Insomnia — not covered.
• Autism spectrum, Tourette syndrome, opioid-use disorder — covered in expanded programs but not in Tennessee.

For comparison, Pennsylvania’s medical program covers 24 qualifying conditions; Maryland 22 (post-Maryland Medical Cannabis Commission expansion); New Jersey expanded to over 20 conditions; Florida includes chronic nonmalignant pain and PTSD. Tennessee’s nine-item list covers a fraction of the patient demographic that medical-cannabis programs typically serve.

Practical Reach — Who Can Actually Use This Defense

The carve-out works for a narrow practical population:

• Families of children with intractable epilepsy — the original intended beneficiaries when the 2014 SB 2531 carve-out was passed (sometimes referred to in TN policy discussion as "the Charlotte’s Web families"). High-CBD/low-THC oils with strong seizure-reduction evidence base.
• ALS patients — small population, end-of-life trajectory.
• End-stage cancer patients — particularly those experiencing wasting, treatment-induced nausea, or treatment-resistant pain.
• Multiple sclerosis — particularly for spasticity.
• Parkinson’s — especially for tremor and sleep complaints in advanced disease.
• HIV/AIDS, sickle cell, IBD — smaller numbers but real.

For everyone else — the chronic-pain and PTSD-driven population that medical-cannabis programs typically serve in volume — the law is functionally inaccessible.

Physician Requirements

Per T.C.A. § 63-1-127, the qualifying-condition diagnosis letter must come from a Tennessee-licensed M.D. or D.O. Physician letters are valid for six months and must be renewed. Tennessee physicians who participate must navigate:

• Practitioner-licensure compliance (Tennessee Department of Health, Boards of Medical and Osteopathic Examiners).
• Federal DEA-prescriber liability concerns — even though CBD oil under 0.3% THC is federally hemp-derived, the Tennessee § 39-17-402(16)(F) framework permits up to 0.9% THC, exceeding the federal threshold.
• Pediatric considerations — many of the qualifying-condition recipients are children (intractable epilepsy), implicating pediatric-prescribing protocols.

The 0.9% THC Ceiling vs. the 0.3% Federal Hemp Ceiling

One often-overlooked feature: the Tennessee carve-out permits CBD oil with THC content up to 0.9%, while the federal hemp definition under the 2018 Farm Bill (and as tightened by November 2025 federal funding-bill provisions effective around November 12, 2026) caps hemp-derived THC at 0.3% delta-9 THC by dry weight. Oils between 0.3% and 0.9% THC under the Tennessee carve-out are not federally hemp — they sit within the federal Schedule III cannabis category as of December 2025. Patients sourcing such oils from out-of-state programs cross federal interstate-commerce restrictions on Schedule III substances.

Adding Conditions — Why None Has Been Added

The statute permits the Tennessee Medical Cannabis Commission to add conditions by rule. None has been added to date. The TMCC’s study-only posture, the General Assembly’s consistent inaction on the Commission’s recommendations, and the lack of patient-advocate or treating-clinician majority on the Commission have combined to keep the list at the 2021 expansion baseline. Reform advocates — particularly TN NORML, the Tennessee Medical Cannabis Alliance (TMCA), and the Marijuana Policy Project — have repeatedly pressed for chronic pain and PTSD to be added.

What Patients Should Know

If a Tennessee patient or family is considering using the § 39-17-402(16)(F) defense:

• Confirm the diagnosis is on the qualifying list (above).
• Obtain a letter from a Tennessee-licensed M.D. or D.O. confirming the diagnosis. The letter must be current within 6 months.
• Source a manufacturer-labeled CBD oil (manufacturer name, expiration, batch/lot, THC concentration < 0.9%) from a state where such oil is legally sold.
• Obtain a written legal order or recommendation from that state’s program (if available) authorizing the oil.
• Maintain documentation continuously while in possession of the oil.
• Understand: this is a defense at trial, not protection from arrest. Collateral consequences (employment, federal clearance, immigration, child-custody) may still attach.

Patients should consult a qualified Tennessee criminal-defense attorney before relying on the affirmative defense in any specific factual context. See advocacy and legal-referral page.

Related on this site: TN CBD-Oil Affirmative Defense, TACIR Medical-Cannabis Readiness Study, Tennessee Medical Cannabis Commission....